Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01480232 · ClinicalTrials.gov registry record · Phase 2
A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence
A Phase 2 study, sponsored by A. Eden Evins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 345
- Enrollment target
NCT01480232 is a Phase 2 study that was terminated before completion, run by A. Eden Evins. The registered enrollment target is 345 participants.
The verdict
NCT01480232, a Phase 2 study, was terminated before completion, sponsored by A. Eden Evins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 345 participants
- Enrollment target
Study Summary
This study is designed to evaluate the initial evidence for efficacy of the investigational medicine, EVP-6124, to improve smoking cessation outcomes with and without a standard taper of nicotine replacement therapy (NRT) in healthy nicotine dependent smokers
Interventions
- DRUG Placebo Capsule
- DRUG EVP-6124
- DRUG NicoDerm Patch (Active)
- DRUG NRT Patch (Placebo)
- BEHAVIORAL Brief Supportive and Behavioral Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2011-12 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01480232
The ClinicalTrials.gov registry entry for NCT01480232 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is A. Eden Evins, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo Capsule is the first listed.
NCT01480232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01480232 about?
NCT01480232 is a clinical study titled "A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence". This study is designed to evaluate the initial evidence for efficacy of the investigational medicine, EVP-6124, to improve smoking cessation outcomes with and without a standard taper of nicotine replacement therapy (NRT) in healthy nicotine dependent smokers
What is the current status of trial NCT01480232?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2011-12. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01480232?
The interventions under investigation include: Placebo Capsule (DRUG), EVP-6124 (DRUG), NicoDerm Patch (Active) (DRUG), NRT Patch (Placebo) (DRUG), Brief Supportive and Behavioral Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT01480232?
This trial is sponsored by A. Eden Evins, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.